{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:40:46Z","timestamp":1773337246912,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chagas disease is a chronic parasitic infection endemic to Latin America that affects more than 7 million people and is increasingly spreading worldwide due to human migration.\n                      <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                      is the etiological agent of this disease, for which no effective vaccine has yet been approved for human use. We previously developed a heterologous chimeric immunogen, CruSEG, composed of the N-terminal domain of the major cysteine protease cruzipain (Nt-Cz) fused to a genetically detoxified mutant of the staphylococcal superantigen G (SEGN24A). This modified superantigen preserves innate immune activation while avoiding deleterious T-cell effects associated with native superantigens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here, we evaluated the immunogenicity and protective efficacy of CruSEG using different vaccination strategies, including recombinant protein formulated with CpG-ODN,oral DNA immunization delivered by attenuated\n                      <jats:italic>Salmonella enterica<\/jats:italic>\n                      , and a heterologous prime\u2013boost regimen combining both platforms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All vaccination protocols induced Nt-Cz\u2013specific immune responses, albeit with distinct qualitative profiles. Recombinant protein vaccination elicited robust humoral immunity characterized by Th1-skewed IgG2a responses and strong parasite neutralizing activity, whereas DNA delivery preferentially promoted potent cellular immunity, including polyfunctional CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and IFN-\u03b3\u2013producing CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. The prime\u2013boost strategy generated a broader immune profile but did not confer superior protection compared with homologous regimens. Upon challenge with\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      strains belonging to different discrete typing units, vaccinated mice exhibited significant reductions in parasitemia during the acute phase and sustained control of parasite burden and tissue damage during chronic infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion-conclusions<\/jats:title>\n                    <jats:p>Although sterilizing immunity was not achieved, the attenuation of parasite persistence and pathology represents a biologically relevant outcome. Collectively, these findings demonstrate that incorporating a detoxified bacterial superantigen into chimeric antigens across multiple platforms enhances immune quality and protective efficacy, highlighting engineered superantigens as promising immune modulators for the development of effective vaccines against Chagas disease<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1788924","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:49:01Z","timestamp":1773298141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Protective immunity against Chagas disease induced by a superantigen-based chimeric DNA vaccine delivered by attenuated Salmonella"],"prefix":"10.3389","volume":"17","author":[{"given":"Mar\u00eda Bel\u00e9n","family":"Antonoglou","sequence":"first","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"S\u00e1nchez Alberti","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]},{"name":"Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiolog\u00eda, Parasitolog\u00eda e Inmunolog\u00eda, and Instituto de Microbiolog\u00eda y Parasitolog\u00eda M\u00e9dica (IMPaM), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Mar\u00eda","family":"Redolfi","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto Ernesto","family":"Bivona","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]},{"name":"Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiolog\u00eda, Parasitolog\u00eda e Inmunolog\u00eda, and Instituto de Microbiolog\u00eda y Parasitolog\u00eda M\u00e9dica (IMPaM), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Noli Truant","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Sarratea","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]},{"name":"Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiolog\u00eda, Parasitolog\u00eda e Inmunolog\u00eda, and Instituto de Microbiolog\u00eda y Parasitolog\u00eda M\u00e9dica (IMPaM), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia Nader","family":"Motta","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Luis","family":"Malchiodi","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]},{"name":"Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiolog\u00eda, Parasitolog\u00eda e Inmunolog\u00eda, and Instituto de Microbiolog\u00eda y Parasitolog\u00eda M\u00e9dica (IMPaM), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa Mariel","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Universidad de Buenos Aires, Facultad de Farmacia y Bioqu\u00edmica, Departamento de Microbiolog\u00eda, Inmunolog\u00eda, Biotecnolog\u00eda y Gen\u00e9tica, C\u00e1tedra de Inmunolog\u00eda","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Estudios de la Inmunidad Humoral \"Prof. Ricardo A. Margni\" (IDEHU), UBA-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12443","article-title":"Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile","volume":"20","author":"Salvador","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165658","article-title":"Chagas disease vaccine design: The search for an efficient Trypanosoma cruzi immune-mediated control","volume":"1866","author":"Bivona","year":"2020","journal-title":"BBA-Mol Basis Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100972","article-title":"Challenges and advancements in the development of vaccines and Therapies against Chagas disease","volume":"5","author":"Pinazo","year":"2024","journal-title":"Lancet Microbe"},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2741\/4473","article-title":"Gene therapy using bacterial vectors","volume":"22","author":"Celec","year":"2017","journal-title":"Front Biosci - Landm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2024.07.010","article-title":"Microbial messengers: nucleic acid delivery by bacteria","volume":"43","author":"Heggie","year":"2025","journal-title":"Trends Biotechnol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.003","article-title":"New insights in mucosal vaccine development","volume":"30","author":"Pavot","year":"2012","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jam.13446","article-title":"Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts","volume":"123","author":"Szatraj","year":"2017","journal-title":"J Appl Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00530-2","article-title":"Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium","volume":"19","author":"Woo","year":"2001","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i6.939","article-title":"Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H. pylori ureB and IL-2","volume":"13","author":"Xu","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4161\/hv.4.3.6314","article-title":"Genetic immunization: Bacteria as DNA vaccine delivery vehicles","volume":"4","author":"Becker","year":"2008","journal-title":"Hum Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01163-07","article-title":"Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi","volume":"76","author":"Cazorla","year":"2008","journal-title":"Infect Immun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/infdis\/jiu480","article-title":"Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis","volume":"211","author":"Cazorla","year":"2015","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02190-14","article-title":"Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge","volume":"82","author":"Matos","year":"2014","journal-title":"Infect Immun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0006384","DOI":"10.1371\/journal.pntd.0006384","article-title":"Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine","volume":"12","author":"Bivona","year":"2018","journal-title":"PloS Negl Trop Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00128","article-title":"Mucosal heterologous prime\/boost vaccination induces polyfunctional systemic immunity improving protection against Trypanosoma cruzi","volume":"11","author":"Sanchez Alberti","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565142","article-title":"Cruzipain and its physiological inhibitor Chagasin, a promising DNA-based therapeutic vaccine protects from tissue damage caused by T. cruzi","volume":"11","author":"Cerny","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1293351","article-title":"Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment","volume":"5","author":"P\u00e9rez Jorge","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c15237","article-title":"Innovative applications of bacteria and their derivatives in targeted tumor therapy","volume":"19","author":"Zhu","year":"2025","journal-title":"ACS Nano"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14110800","article-title":"Superantigens, a paradox of the immune response","volume":"14","author":"Noli Truant","year":"2022","journal-title":"Toxins"},{"key":"B21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/prot.21388","article-title":"Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor V\u03b28.2","volume":"68","author":"Fern\u00e1ndez","year":"2007","journal-title":"Proteins"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.142471","article-title":"Crystal structure of staphylococcal enterotoxin G (SEG) in complex with mouse T-cell receptor \u03b2 chain","volume":"286","author":"Fernandez","year":"2011","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/652872","article-title":"Redirection of the immune response to the functional catalytic domain of cruzipain improves protective immunity against Trypanosoma cruzi infection","volume":"202","author":"Cazorla","year":"2010","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01279","article-title":"Heterologous chimeric construct comprising a modified bacterial superantigen and a cruzipain domain confers protection against Trypanosoma cruzi infection","volume":"11","author":"Antonoglou","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies","volume":"4","author":"Charan","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(91)90331-9","article-title":"Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system","volume":"145","author":"Karlsson","year":"1991","journal-title":"J Immunol Methods"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-6851(03)00093-8","article-title":"Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR","volume":"129","author":"Cummings","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0005300","DOI":"10.1371\/journal.pntd.0005300","article-title":"Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses conferring protection against Trypanosoma cruzi","volume":"11","author":"Matos","year":"2017","journal-title":"PloS Negl Trop Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0010-z","article-title":"Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection","volume":"2","author":"Sanchez Alberti","year":"2017","journal-title":"NaturePJ-Vaccines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.pt.2019.08.006","article-title":"Understanding CD8+ T cell immunity to trypanosoma cruzi and how to improve it","volume":"35","author":"Acosta Rodr\u00edguez","year":"2019","journal-title":"Trends Parasitol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: Ready for prime time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.144","article-title":"Salmonella enterica as a vaccine carrier","volume":"7","author":"Hegazy","year":"2012","journal-title":"Future Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00142-0","article-title":"A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model","volume":"18","author":"Pasetti","year":"2000","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0008-8749(02)00507-5","article-title":"Modulation of the immune response mediated by oral transgene administration of IL-10","volume":"216","author":"El\u00edas","year":"2002","journal-title":"Cell Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/104454999314917","article-title":"DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model","volume":"18","author":"Sin","year":"1999","journal-title":"DNA Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.03.029","article-title":"Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting","volume":"22","author":"Wang","year":"2004","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00597-15","article-title":"Oral immunization with recombinant vaccinia virus prime and intramuscular protein boost provides protection against intrarectal simian-human immunodeficiency virus challenge in Macaques","volume":"23","author":"Thippeshappa","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/092986709788802971","article-title":"Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review","volume":"16","author":"Duschak","year":"2009","journal-title":"Curr Med Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0003010","article-title":"Acute chagas disease: new global challenges for an old neglected disease","volume":"8","author":"Andrade","year":"2014","journal-title":"PloS Negl Trop Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003845.IL-10","article-title":"IL-10 Limits Parasite Burden and Protects against Fatal Myocarditis in a Mouse Model of Trypanosoma cruzi Infection","volume":"188","author":"Roff\u00ea","year":"2013","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1371\/journal.pntd.0000992","article-title":"Regulatory T cells phenotype in different clinical forms of chagas \u2018 Disease","volume":"5","author":"De Araujo","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e15251","DOI":"10.1111\/tan.15251","article-title":"HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19","volume":"103","author":"Farias","year":"2024","journal-title":"HLA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e2575","DOI":"10.1371\/journal.pntd.0002575","article-title":"Polyfunctional T cell responses in children in early stages of chronic trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults","volume":"7","author":"Albareda","year":"2013","journal-title":"PloS Negl Trop Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004657","article-title":"Treatment success in trypanosoma cruzi infection is predicted by early changes in serially monitored parasite-specific T and B cell responses","volume":"10","author":"Alvarez","year":"2016","journal-title":"PloS Negl Trop Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04536.x","article-title":"Multifunctional CD4 +T cells in patients with American cutaneous leishmaniasis","volume":"167","author":"Macedo","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01245-06","article-title":"Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells","volume":"75","author":"Padilla","year":"2007","journal-title":"Infect Immun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-015-0811-8","article-title":"Inflammatory responses and intestinal injury development during acute Trypanosoma cruzi infection are associated with the parasite load","volume":"8","author":"Vazquez","year":"2015","journal-title":"Parasites Vectors"},{"key":"B51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-pathol-020117-043711","article-title":"Pathology and pathogenesis of chagas heart disease","volume":"14","author":"Bonney","year":"2019","journal-title":"Annu Rev Pathol: Mech Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00081-19","article-title":"Low-level parasite persistence drives vasculitis and myositis in skeletal muscle of mice chronically infected with trypanosoma cruzi","volume":"87","author":"Weaver","year":"2019","journal-title":"Infect Immun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03008","article-title":"egc Superantigens impair monocytes\/macrophages inducing cell death and inefficient activation","volume":"10","author":"Noli Truant","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00601-22","article-title":"Delayed Activation of T Cells at the Site of Infection Facilitates the Establishment of Trypanosoma cruzi in Both Naive and Immune Hosts","volume":"8","author":"Padilla","year":"2023","journal-title":"MSphere"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788924\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:49:02Z","timestamp":1773298142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788924\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1788924"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1788924","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1788924"}}